Not so long ago Eli Lilly, the 20 billion$ pharmaceutical company, announced a major restructuring of the company. A part of the restructuring involves the creation of a single Development Centre of Excellence. This centre of excellence has 3 pillars of excellence to drive the development of new molecules into new drugs. From the Theory of Constraints perspective the interesting news is that this major pharmaceutical company is adopting the Critical Chain methodology as their management tool for development projects.
“There are three key pillars from a technology and methodology perspective. One is critical chain methodology—a project management tool that we piloted. One hundred percent of the projects using critical chain methodology are on track, either at or ahead of their milestones, as compared to about 60 percent of our traditional development projects. We will expand this to all of our projects by the end of this year,” is part of the interview with Steven Paul, president of Lilly Research Laboratories.
To read the rest of the interview, please follow this link.
